Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Blended Water Supplies Impact Water Treatment

Where does my water come from? The source(s) of water supplied to cooling towers, boilers, and processes may vary greatly daily or even hourly. The impact this has on water systems must be closely monitored to avoid scale, deposits, corrosion, inefficient water usage, and other negative impacts on operational costs. The New York City water…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Where does my water come from?

The source(s) of water supplied to cooling towers, boilers, and processes may vary greatly daily or even hourly. The impact this has on water systems must be closely monitored to avoid scale, deposits, corrosion, inefficient water usage, and other negative impacts on operational costs.

The New York City water supply is a good example, providing over 1.2 billion gallons/day of domestic water to more than 8 million NYC residents, 1 million users from 4 upstate counties, and the city’s many visitors. The water system is made up of aqueducts, distribution pipes, reservoirs, and water tunnels offering a total system storage capacity of close to 550 billion gallons. There are three separate systems that bring water from upstate to the city to fit this need; the Croton, to the east of the Hudson River, and the Catskill and Delaware on the west.

What is in my water?

Since the opening of the Croton Water Filtration facility in May of 2015 water treatment professionals across the five boroughs have faced issues with a blended water supply. The neighborhoods of New York City often receive a combination of all three water supplies, the Croton, Catskill, and Delaware. Operational decisions about the City’s water supply, including the proportion of water from each of the systems, are often made on an hourly basis, creating a constantly changing chemistry of a building’s incoming water.

There is currently no formal notification system in place as to when a change in water supply might occur or what the blend could consist of. When Croton water is introduced to the system there could be areas within the same borough that are 100% Croton water or 100% Catskill/Delaware water, and others that are blended at varying percentages. Conductivity measurements are relied upon to gain an understanding of what water source you’re dealing with at each location throughout the city.

In general, the conductivity of the Catskill/Delaware supply is in the 90-100 µmho range while the conductivity of the Croton water is consistently in the 350-500 µmho range. For many facilities, when the make-up water has a conductivity greater than 100, it is assumed some level of blending is taking place. The chart below details some key differences in the inorganic chemistry of the water supplies:

How does this affect my water treatment?

From a water treatment perspective, fluctuating supply/makeup water sources present significant issues for system control. To understand this concept, it’s important to understand cycles of concentration (COC). Cooling tower cycles are typically controlled by the conductivity of the water in the system. When the conductivity reaches a predetermined set point, the controller bleeds water from the system and replaces it with fresh makeup water. The makeup water has a lower concentration of salts and dilutes the system water. With consistent makeup water, this control method is simple and quite effective because water treatment professionals can predict the levels of dissolved solids in the system water (important for inhibitor choice), determine hold times (the length of time the water stays in the system), and estimate water use.

Cooling tower treatment, for example, commonly bases the cycles of concentration calculation upon conductivity readings. The incoming city water conductivity is multiplied by the targeted number of cycles to use as the conductivity set point. Over-cycling could lead to issues with scale deposition when the concentration of dissolved solids gets above the saturation point. Under-cycling can lead to unnecessary water use, lower operational efficiency, and depending on control method, inaccurate inhibitor residuals. A constantly changing water supply makes it almost impossible to consistently maintain the targeted cycles for a specific system. This is particularly true when there is no way of knowing what type of water you could be receiving at a facility at any given time. Changing the chemistry of the makeup water also changes the target cycles. A varying water supply requires consistent on-site testing of the makeup water and an experienced water treatment professional to effectively manage the fluctuating conditions.

Chem-Aqua has the perfect blend of expertise and experience to manage your changing water demands. Contact a local representative today to review your water treatment program.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. Holland & Knight said hospitals will be eligible for NTAP reimbursement for use of Aidoc’s CARE Body CT Multi-Triage beginning Oct. 1, 2026, with supplemental payments continuing for three years.

  • 01Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage.
  • 02Holland & Knight said CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage, with hospitals eligible for NTAP reimbursement beginning Oct. 1, 2026, with supplemental payments continuing for three years.

Sep 23, 2026

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512